Daily Bulletin

Men's Weekly

.

PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology

  • Written by PR Newswire Asia - Daily Bulletin Au RSS

- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically

- Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma

MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular...

Read more: PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant...

Business News

Why More Aussie Tradies Are Moving Away From Paid Ads

Across Australia, a lot of tradies are busy. There’s no shortage of demand in industries like plumbing, electrical, landscaping, and building. But being busy doesn’t always mean running a smooth or...

Daily Bulletin - avatar Daily Bulletin

Why Careers In The Defence Industry Are Growing Rapidly

The defence sector has evolved far beyond traditional roles, opening doors to a wide range of opportunities across technology, engineering, intelligence, and operations. This is where defense industry...

Daily Bulletin - avatar Daily Bulletin

Strategic partnerships to enable global acceleration for Aussie fashion brands: SHEIN Xcelerator launches

SHEIN Xcelerator is introducing a more agile, demand-led operating model, allowing brands to scale while retaining control over creative direction and identity. For fashion brands, the pressure t...

Daily Bulletin - avatar Daily Bulletin